When you search for Jeff Knight net worth, you're probably not looking for a Nike billionaire or a Hollywood A-lister. You are likely looking for the man behind the scenes of high-stakes biotech or perhaps the Florida entrepreneur who dominated the local entertainment and telecom scene before a tragic headline changed everything.
Net worth isn't just a static number on a screen. It’s a moving target of stock options, private equity, and—sometimes—the cost of legal fallout.
✨ Don't miss: Gregg Davis Net Worth: What Most People Get Wrong
Honestly, the "Jeff Knight" most people are tracking in 2026 is Jeff E. Knight, the Chief Operating Officer of Crinetics Pharmaceuticals. While he isn't buying islands like Elon Musk, his financial trajectory is a masterclass in how modern executive compensation actually works.
The $5 Million Biotech Play
Most people see a "net worth" estimate and think it's cash in a bank account. It's not. For Jeff E. Knight, his wealth is tied almost entirely to the success of Crinetics Pharmaceuticals (CRNX).
As of early 2026, Knight’s estimated net worth sits comfortably around $5 million.
Now, $5 million might sound "low" for a C-suite executive at a major pharma company, but you've got to look at the "burn and earn" cycle of his trades. In 2024 alone, Knight was incredibly active. He didn't just sit on his shares; he moved them. He acquired over 166,000 shares but also cashed out on roughly 120,000 shares, bringing in over $3.1 million in a single year.
That is liquidity. That is how you pay for the lifestyle while keeping your "official" net worth tied to the company's performance.
Breaking Down the Compensation
If you look at the SEC filings, the way Knight makes his money is pretty standard for the industry, yet eye-opening for the average person:
- Base Salary: Usually around $490,000 to $500,000.
- The Real Money: Stock and option awards that often exceed $3.4 million annually.
- The "Kicker": Performance bonuses and incentive plans that add another $200k+ to the pile.
Basically, his net worth is a reflection of the stock market's faith in Crinetics. If their endocrine disease pipeline hits, that $5 million could double. If it fails, those options are just paper.
The Other Jeff Knight: A Florida Cautionary Tale
There is another Jeff Knight (often spelled Jeffry) who pops up in these searches, and his financial story is much darker. This Jeff Knight was the powerhouse behind Jannus Live in St. Petersburg and Knight Enterprises, a massive telecommunications contractor.
His net worth was once estimated in the tens of millions, driven by cable installation contracts across the Southeast. However, wealth isn't a shield against reality.
📖 Related: Why 325 Chestnut St Philadelphia PA Matters for the City’s Business Future
In 2025, a tragic boating accident in Clearwater Harbor involving a ferry led to Knight "stepping down" from his affiliations with Jannus Live. When a high-net-worth individual is forced out of their own ventures, the valuation of their "worth" becomes incredibly murky. Private companies like Knight Enterprises don't have public stock tickers. We can't see the balance sheets.
What we do know? Legal battles and the loss of operational control can vaporize a net worth faster than a bad day on Wall Street.
Why the Numbers You See Online Are Often Wrong
I'll be blunt: most "celebrity net worth" sites are guessing. They see a guy named Jeffrey Knight who is a top-tier financial advisor at New York Life (who manages hundreds of millions in assets) and they accidentally attribute those assets to his personal wealth.
They aren't the same thing.
The Advisor vs. The Executive
- Jeffrey Dion Knight (Financial Pro): Manages money, but his personal net worth isn't the $500M+ "AUM" (Assets Under Management) you see in reports.
- Jeff E. Knight (Biotech COO): His wealth is transparent because the SEC forces him to tell us when he sells a single share.
- Phil Knight (Nike): The $35 billion elephant in the room. People often click on Jeff's name hoping he’s an heir. (He’s not).
The Complexity of Executive Wealth
You've got to understand that for a guy like Jeff E. Knight, his "worth" is also a liability.
If he sells too much stock, investors panic. They think he knows something they don't. If he doesn't sell, he's "paper rich" but can't buy a sandwich with a share of CRNX. This is the "Golden Handcuff" scenario.
He is currently holding about 87,491 shares of Crinetics. At a price of roughly $56 per share, that’s $4.9 million right there. But he also has tax obligations on every grant. In March 2024, he had to shell out over $163,000 just to cover taxes on vested shares.
Wealth at this level is a constant game of chess with the IRS.
What This Means for You
Looking at Jeff Knight’s net worth reveals a few cold, hard truths about building wealth in the 2020s.
First, salary is a trap. You don't get to a multi-million dollar net worth by just collecting a paycheck. You get there through equity. Knight’s salary is less than 15% of his total annual compensation.
Second, diversification is key, but concentration is how you get rich. Knight is "all in" on biotech. It’s risky, but it’s the only reason he’s on the radar.
Actionable Steps to Track and Build Similar Worth
If you are trying to track a specific executive's wealth or build your own, stop looking at "gossip" sites and start looking at the source:
- Check SEC Form 4: If you want the truth on Jeff Knight or any other executive, go to the SEC EDGAR database. It shows every buy and sell.
- Focus on "Total Compensation": Don't just look at a bank balance. Look at the ability to generate cash flow through options.
- Watch the Industry Trends: Jeff Knight’s wealth is tied to the biotech sector. When interest rates drop, biotech usually booms, and his net worth will likely climb alongside it.
The story of Jeff Knight—whether the biotech COO or the Florida businessman—reminds us that net worth is fragile. It’s built on reputation, stock performance, and the ability to stay in the game.
Keep an eye on the CRNX ticker; that's the real barometer of where Jeff Knight stands today.
Next Steps: Review the latest SEC Form 4 filings for Crinetics Pharmaceuticals to see if any major sell-offs have occurred in the last 30 days, as this is the most accurate way to verify his current liquid position.**